This company has been marked as potentially delisted and may not be actively trading. Cerecor (CERC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CERC vs. MOR, GMTX, CALT, ZYME, MBX, SBTX, AVTE, BIOA, NLTX, and CYBNShould you be buying Cerecor stock or one of its competitors? The main competitors of Cerecor include MorphoSys (MOR), Gemini Therapeutics (GMTX), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), MBX Biosciences (MBX), Silverback Therapeutics (SBTX), Aerovate Therapeutics (AVTE), BioAge Labs (BIOA), Neoleukin Therapeutics (NLTX), and Cybin (CYBN). Cerecor vs. Its Competitors MorphoSys Gemini Therapeutics Calliditas Therapeutics AB (publ) Zymeworks MBX Biosciences Silverback Therapeutics Aerovate Therapeutics BioAge Labs Neoleukin Therapeutics Cybin Cerecor (NASDAQ:CERC) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation. Does the media refer more to CERC or MOR? In the previous week, Cerecor's average media sentiment score of 0.16 beat MorphoSys' score of 0.00 indicating that Cerecor is being referred to more favorably in the media. Company Overall Sentiment Cerecor Neutral MorphoSys Neutral Do institutionals & insiders hold more shares of CERC or MOR? 62.8% of Cerecor shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 45.7% of Cerecor shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, CERC or MOR? Cerecor has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Which has stronger valuation & earnings, CERC or MOR? Cerecor has higher earnings, but lower revenue than MorphoSys. Cerecor is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCerecor$6.70M166.22-$63.50M-$0.57-20.35MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Is CERC or MOR more profitable? MorphoSys has a net margin of -226.79% compared to Cerecor's net margin of -1,194.82%. Cerecor's return on equity of -261.82% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Cerecor-1,194.82% -261.82% -133.96% MorphoSys -226.79%-694.31%-22.55% SummaryCerecor beats MorphoSys on 8 of the 12 factors compared between the two stocks. Get Cerecor News Delivered to You Automatically Sign up to receive the latest news and ratings for CERC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CERC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERC vs. The Competition Export to ExcelMetricCerecorPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.11B$832.52M$5.82B$9.94BDividend YieldN/A4.84%6.70%4.53%P/E Ratio-20.351.1676.2126.11Price / Sales166.2226.54557.45121.74Price / CashN/A19.5625.7029.11Price / Book52.736.7311.486.09Net Income-$63.50M-$3.82M$3.29B$266.19M Cerecor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CERCCerecorN/A$11.60+14.2%N/A+50.6%$1.11B$6.70M-20.3531Gap UpMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730GMTXGemini TherapeuticsN/A$59.650.0%N/A+21.0%$2.58BN/A-59.6530CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ZYMEZymeworks2.4109 of 5 stars$14.01-5.4%$21.43+53.0%+30.2%$1.05B$122.87M-9.34460News CoveragePositive NewsAnalyst RevisionMBXMBX Biosciences2.6358 of 5 stars$14.57-3.4%$37.63+158.2%N/A$489.47MN/A-3.2136News CoverageSBTXSilverback TherapeuticsN/A$11.62-9.6%N/A-11.4%$418.99MN/A-4.8083High Trading VolumeAVTEAerovate TherapeuticsN/A$7.90-2.2%N/A-88.3%$228.98MN/A-2.6420News CoveragePositive NewsHigh Trading VolumeBIOABioAge LabsN/A$4.65-5.7%N/AN/A$176.74MN/A0.00N/ANews CoveragePositive NewsHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$18.48-1.9%N/A-43.0%$173.68MN/A-5.9490News CoverageCYBNCybin1.8676 of 5 stars$6.24-16.6%$85.00+1,262.2%N/A$147.20MN/A-1.4250News CoverageHigh Trading Volume Related Companies and Tools Related Companies MorphoSys Alternatives Gemini Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Zymeworks Alternatives MBX Biosciences Alternatives Silverback Therapeutics Alternatives Aerovate Therapeutics Alternatives BioAge Labs Alternatives Neoleukin Therapeutics Alternatives Cybin Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CERC) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cerecor Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cerecor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
